Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect?

Eur Urol. 2024 Oct;86(4):366-368. doi: 10.1016/j.eururo.2024.05.027. Epub 2024 Jun 14.

Authors

Amanda A Myers¹, Wei Shen Tan¹, Valentina Grajales¹, Hyunsoo Hwang¹, Kelly K Bree¹, Neema Navai¹, Byron H Lee¹, Colin P N Dinney¹, Ashish M Kamat²

Affiliations

¹ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: [email protected].

PMID: 38879371
DOI: 10.1016/j.eururo.2024.05.027

No abstract available

Publication types

Letter
Editorial

MeSH terms

Adjuvants, Immunologic / therapeutic use
Administration, Intravesical
BCG Vaccine* / therapeutic use
Humans
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / pathology

Substances

BCG Vaccine
Adjuvants, Immunologic